Efficacy of remimazolam tosilate versus propofol for total intravenous anaesthesia in urological surgery: A randomised clinical trial
Authors' conclusion
Remimazolam demonstrated noninferior efficacy to propofol combined with remifentanil and cisatracurium for TIVA in patients undergoing urological surgery.
Study context
- Population
- Adults undergoing elective urological surgeryall completed
- Participants
- 146 adults
- Comparison
- Remimazolam (RMZ) vs PROP
- Primary endpoint
- TIVA success rate
Methodological detailsprospective, single-blind, noninferiority, single-centre, Single centre, 1 January 2022 to 30 March 2022
- Prospective
- Single-blind
- Noninferiority
- Single-centre
- Single centre, 1 January 2022 to 30 March 2022
Primary result
As reported in the abstract
RMZ
100
%
PROP
98.6%
Secondary outcomes
Total ephedrine consumption during anaesthesia
P = 0.0002
Controllability of anaesthesia depth, anaesthesia and surgery characteristics, vital signs
- No significant differences between the groups
Safety
Hypotension during anaesthesia
P = 0.016
| Outcome | RMZ | PROP | P value |
|---|---|---|---|
| Injection pain | 0 | 76.7% | P < 0.001 |
Original publication
Efficacy of remimazolam tosilate versus propofol for total intravenous anaesthesia in urological surgery: A randomised clinical trial. Eur J Anaesthesiol. Published 2 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →